| Aerie Pharmaceuticals is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Co.'s commercial products include Rhopressa®, which is a once-daily eye drop to lower elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension; and Rocklatan®, which is a once-daily fixed-dose combination of Rhopressa® and latanoprost, the prescribed drug for the treatment of patients with open-angle glaucoma. Co. is developing three sustained-release implants focused on retinal diseases, AR-1105, AR-13503 SR and AR-14034 SR. We show 35 historical shares outstanding datapoints in our AERI shares outstanding history coverage, used to compute AERI market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AERI market cap history over the course of time is important for investors
interested in comparing AERI's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AERI versus a peer is one thing; comparing
AERI market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AERI can fluctuate over the course of history.
With this page we aim to empower investors researching AERI by allowing them to research the AERI market cap history.